Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
The 2 Most Critical Elements of MSL Territory Excellence with Julie Montiel
Summary
In this episode, Tom Caravela is joined by Julie Montiel to explore the nuances of MSL territory excellence and the critical role of scientific acumen. They delve into strategies for achieving scientific acumen and crafting effective, individualized territory plans. The conversation highlights the significance of pre-call and post-call planning in managing territories, as well as adapting strategies for virtual and digital engagements. Julie shares tips to enhance virtual presentation skills, concluding with a recap on creating a plan for territory excellence. The episode wraps up with closing remarks on the importance of key MSL strategies and a call to action for listeners.
My guest today is Julie Montiel, the National Scientific Director, Lymphoma/Myeloid MSL at The Janssen. We talk about the two most critical of MSL territory excellence.
In this episode we discuss:
- Julie’s background
- The two most critical elements
- How MSLs improve their performance
- What is scientific acumen
- Why is scientific acumen the most important element of territory excellence
- What does excellence in scientific acumen look like?
- Every territory is different
- Applying principles to a virtual type of scenario
- How MSLs bring all of these pieces of information together to build strategic territory excellence
MSL territory excellence, scientific acumen, virtual presentation skills, strategic territory planning, MSL performance improvement
Related Topics
You May Also Like
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care
Article
iNIZIO
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis